Medicamen Biotech partners with South African business conglomerate
The recent EU approval of MBL's plant has opened new avenues to explore such opportunities
The recent EU approval of MBL's plant has opened new avenues to explore such opportunities
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA
In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
Standalone profit from operations for Q4-2024 were Rs. 108 crore
This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Subscribe To Our Newsletter & Stay Updated